US03209R1032 - Common Stock

**AMPH** gets a fundamental rating of **6** out of 10. The analysis compared the fundamentals against 195 industry peers in the **Pharmaceuticals** industry. While **AMPH** has a great profitability rating, there are some minor concerns on its financial health. **AMPH** is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make **AMPH** suitable for value investing!

Measured over the past 3 years, the **Average Return On Invested Capital** for **AMPH** is significantly below the industry average of **17.70%**.

The last **Return On Invested Capital** (**12.93%**) for **AMPH** is above the 3 year average (**11.94%**), which is a sign of increasing profitability.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 9.82% | ||

ROE | 23% | ||

ROIC | 12.93% |

ROA(3y)10.22%

ROA(5y)7.84%

ROE(3y)17.58%

ROE(5y)13.18%

ROIC(3y)11.94%

ROIC(5y)N/A

Looking at the **Profit Margin**, with a value of **22.87%**, **AMPH** belongs to the top of the industry, outperforming **94.30%** of the companies in the same industry.

Looking at the **Operating Margin**, with a value of **31.29%**, **AMPH** belongs to the top of the industry, outperforming **94.82%** of the companies in the same industry.

The **Gross Margin** of **AMPH** (**54.32%**) is better than **63.21%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 31.29% | ||

PM (TTM) | 22.87% | ||

GM | 54.32% |

OM growth 3Y114.39%

OM growth 5YN/A

PM growth 3Y276.41%

PM growth 5YN/A

GM growth 3Y10.26%

GM growth 5Y8.62%

Compared to 1 year ago, **AMPH** has a worse debt to assets ratio.

Looking at the **Altman-Z score**, with a value of **2.80**, **AMPH** is in the better half of the industry, outperforming **75.13%** of the companies in the same industry.

The **Debt to FCF ratio** of **AMPH** (**3.69**) is better than **87.56%** of its industry peers.

A Debt/Equity ratio of **0.88** indicates that **AMPH** is somewhat dependend on debt financing.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.88 | ||

Debt/FCF | 3.69 | ||

Altman-Z | 2.8 |

ROIC/WACC1.52

WACC8.51%

A Current Ratio of **2.18** indicates that **AMPH** has no problem at all paying its short term obligations.

The **Current ratio** of **AMPH** (**2.18**) is worse than **63.21%** of its industry peers.

A Quick Ratio of **1.72** indicates that **AMPH** should not have too much problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 2.18 | ||

Quick Ratio | 1.72 |

The **Earnings Per Share** has grown by an impressive **75.47%** over the past year.

Measured over the past years, **AMPH** shows a very strong growth in **Earnings Per Share**. The EPS has been growing by **70.36%** on average per year.

EPS 1Y (TTM)75.47%

EPS 3Y72.76%

EPS 5Y70.36%

EPS Q2Q%67.74%

Revenue 1Y (TTM)30.4%

Revenue growth 3Y22.59%

Revenue growth 5Y16.94%

Sales Q2Q%22.72%

Based on estimates for the next years, **AMPH** will show a decrease in **Earnings Per Share**. The EPS will decrease by **-4.87%** on average per year.

The **Revenue** is expected to grow by **1.16%** on average over the next years.

EPS Next Y17.3%

EPS Next 2Y16.31%

EPS Next 3Y16.21%

EPS Next 5Y-4.87%

Revenue Next Year17.19%

Revenue Next 2Y11.5%

Revenue Next 3Y10.69%

Revenue Next 5Y1.16%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

With a **Price/Earnings** ratio of **10.87**, the valuation of **AMPH** can be described as very reasonable.

90.16% of the companies in the same industry are more expensive than **AMPH**, based on the **Price/Earnings** ratio.

The average S&P500 **Price/Earnings** ratio is at **28.63**. **AMPH** is valued rather cheaply when compared to this.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 10.87 | ||

Fwd PE | 9.06 |

Based on the **Enterprise Value to EBITDA** ratio, **AMPH** is valued cheaper than 90.16% of the companies in the same industry.

Based on the **Price/Free Cash Flow** ratio, **AMPH** is valued cheaper than 89.64% of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 12.29 | ||

EV/EBITDA | 8.44 |

The low **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

PEG (NY)0.63

PEG (5Y)0.15

EPS Next 2Y16.31%

EPS Next 3Y16.21%

No dividends for **AMPH**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**AMPHASTAR PHARMACEUTICALS IN**

NASDAQ:AMPH (6/21/2024, 7:00:00 PM)

After market: 40.45 0 (0%)**40.45**

**+0.67 (+1.68%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.98B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 10.87 | ||

Fwd PE | 9.06 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)0.63

PEG (5Y)0.15

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 9.82% | ||

ROE | 23% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 31.29% | ||

PM (TTM) | 22.87% | ||

GM | 54.32% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.43

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.88 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 2.18 | ||

Quick Ratio | 1.72 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)75.47%

EPS 3Y72.76%

EPS 5Y

EPS Q2Q%

EPS Next Y17.3%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)30.4%

Revenue growth 3Y22.59%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y